Next Article in Journal
Molecular Scavengers, Oxidative Stress and Cardiovascular Disease
Previous Article in Journal
Associations between Plasma Biomarkers and Cognition in Patients with Alzheimer’s Disease and Amnestic Mild Cognitive Impairment: A Cross-Sectional and Longitudinal Study
Open AccessArticle

BOne HEalth ManagEment in Patients with Early Breast Cancer: A Retrospective Italian Osteoncology Center “Real-Life” Experience (BOHEME Study)

1
Osteoncology and Rare Tumors Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy
2
Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy
3
IT Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2019, 8(11), 1894; https://doi.org/10.3390/jcm8111894
Received: 12 September 2019 / Revised: 16 October 2019 / Accepted: 4 November 2019 / Published: 6 November 2019
(This article belongs to the Section Oncology)
Background: We assessed the real-life clinical impact of bone health management in patients with breast cancer (BC) receiving adjuvant endocrine therapy at an Italian Osteoncology Center. Methods: Pre- and post-menopausal women undergoing adjuvant endocrine therapy for early-stage BC who came to our institute for their first bone health evaluation from January 2011 to June 2016 were considered in this retrospective observational study. Results: 1125 pre- and post-menopausal early-stage BC patients (209 and 916, respectively) were evaluated. Median age was 61 years (range 26–88). In the pre-menopausal group, spinal x-ray revealed that 10 patients (4.7%) had a morphometric vertebral fracture. Higher age (OR: 1.14; 95% CI: 1.01–1.29) and bone mineral density (BMD) ≤ −2.5 (OR: 14.45; 95% CI: 1.70–122.67) were associated with a higher risk of bone fracture. The overall frequency of bone fracture was 17.6% (n = 161) in post-menopausal patients and a lower risk for bone fractures was associated with tamoxifen or other treatments (OR: 0.25; 95% CI: 0.12–0.53), presence of back pain (OR: 1.65; 95% CI: 1.16–2.36), lower BMD (OR: 2.09 in patients with T-score ≤ 2.5; 95% CI: 1.21–3.59) and lower vitamin D levels (OR: 1.57 in patients with ≤ 10 ng/mL; 95% CI: 1.05–2.34) in univariate analysis. Conclusion: Our findings confirm that bone health management should be an integral part of long-term cancer care.
Keywords: bone health; breast cancer; hormone therapy; bone-modifying agents; denosumab; zoledronic acid bone health; breast cancer; hormone therapy; bone-modifying agents; denosumab; zoledronic acid
MDPI and ACS Style

Recine, F.; Bongiovanni, A.; Foca, F.; Mercatali, L.; Fausti, V.; Calpona, S.; Riva, N.; Vita, A.D.; Liverani, C.; Spadazzi, C.; Miserocchi, G.; Di Menna, G.; Gurrieri, L.; Cocchi, C.; Debonis, S.A.; Vespignani, R.; Ibrahim, T. BOne HEalth ManagEment in Patients with Early Breast Cancer: A Retrospective Italian Osteoncology Center “Real-Life” Experience (BOHEME Study). J. Clin. Med. 2019, 8, 1894.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop